ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more
ProMIS Neurosciences Inc. (PMN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.108x
Based on the latest financial reports, ProMIS Neurosciences Inc. (PMN) has a cash flow conversion efficiency ratio of -1.108x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.18 Million) by net assets ($9.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ProMIS Neurosciences Inc. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how ProMIS Neurosciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ProMIS Neurosciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProMIS Neurosciences Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TIL Limited
NSE:TIL
|
-0.256x |
|
Spanish Mountain Gold Ltd.
OTCQB:SPAUF
|
0.001x |
|
LTR Pharma Ltd
AU:LTP
|
-0.076x |
|
Molinos Juan Semino SA
BA:SEMI
|
0.001x |
|
Lien Chang Electronic Enterprise Co Ltd
TW:2431
|
-0.008x |
|
Spir Group ASA
OL:SPIR
|
0.103x |
|
Walkabout Resources Ltd
AU:WKT
|
-0.073x |
|
Navamedic ASA
OL:NAVA
|
0.047x |
Annual Cash Flow Conversion Efficiency for ProMIS Neurosciences Inc. (2005–2024)
The table below shows the annual cash flow conversion efficiency of ProMIS Neurosciences Inc. from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $16.49 Million | $-27.18 Million | -1.649x | +42.94% |
| 2023-12-31 | $3.75 Million | $-10.84 Million | -2.889x | -130.95% |
| 2022-12-31 | $-1.82 Million | $-17.03 Million | 9.335x | +807.56% |
| 2021-12-31 | $7.16 Million | $-9.44 Million | -1.319x | -130.78% |
| 2020-12-31 | $-1.02 Million | $-4.35 Million | 4.286x | +128.02% |
| 2019-12-31 | $398.12K | $-6.09 Million | -15.296x | -178.69% |
| 2018-12-31 | $1.16 Million | $-6.35 Million | -5.489x | -85.69% |
| 2017-12-31 | $1.53 Million | $-4.53 Million | -2.956x | +89.16% |
| 2016-12-31 | $69.43K | $-1.89 Million | -27.258x | -1342.39% |
| 2015-12-31 | $599.98K | $-1.13 Million | -1.890x | -123.02% |
| 2013-12-31 | $-198.23K | $-1.63 Million | 8.209x | -11.47% |
| 2012-12-31 | $-212.54K | $-1.97 Million | 9.273x | -14.15% |
| 2011-12-31 | $-216.25K | $-2.34 Million | 10.801x | +100.38% |
| 2010-12-31 | $809.08 | $-2.31 Million | -2856.656x | -337161.87% |
| 2009-12-31 | $4.67 Million | $-3.96 Million | -0.847x | -0.91% |
| 2008-12-31 | $3.90 Million | $-3.27 Million | -0.839x | -31.21% |
| 2007-12-31 | $8.45 Million | $-5.40 Million | -0.640x | -165.09% |
| 2006-12-31 | $12.20 Million | $-2.94 Million | -0.241x | +17.15% |
| 2005-12-31 | $4.55 Million | $-1.32 Million | -0.291x | -- |